Skip to main content
PMC home page
Thorax logoLink to Thorax
. 1995 Sep;50(9):1005–1010. doi: 10.1136/thx.50.9.1005

Cysteinyl leukotrienes in asthma: current state of therapeutic evaluation.

I K Taylor 1
PMCID: PMC1021320  PMID: 8539660

Full text

PDF
1006

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arm J. P., Horton C. E., Mencia-Huerta J. M., House F., Eiser N. M., Clark T. J., Spur B. W., Lee T. H. Effect of dietary supplementation with fish oil lipids on mild asthma. Thorax. 1988 Feb;43(2):84–92. doi: 10.1136/thx.43.2.84. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Arm J. P., Lee T. H. Sulphidopeptide leukotrienes in asthma. Clin Sci (Lond) 1993 May;84(5):501–510. doi: 10.1042/cs0840501. [DOI] [PubMed] [Google Scholar]
  3. Arm J. P., Spur B. W., Lee T. H. The effects of inhaled leukotriene E4 on the airway responsiveness to histamine in subjects with asthma and normal subjects. J Allergy Clin Immunol. 1988 Oct;82(4):654–660. doi: 10.1016/0091-6749(88)90979-7. [DOI] [PubMed] [Google Scholar]
  4. Barnes N. C., Piper P. J., Costello J. F. Comparative effects of inhaled leukotriene C4, leukotriene D4, and histamine in normal human subjects. Thorax. 1984 Jul;39(7):500–504. doi: 10.1136/thx.39.7.500. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Barnes P. J. A new approach to the treatment of asthma. N Engl J Med. 1989 Nov 30;321(22):1517–1527. doi: 10.1056/NEJM198911303212206. [DOI] [PubMed] [Google Scholar]
  6. Barnes P. J., Chung K. F., Page C. P. Inflammatory mediators and asthma. Pharmacol Rev. 1988 Mar;40(1):49–84. [PubMed] [Google Scholar]
  7. Bel E. H., Timmers M. C., Dijkman J. H., Stahl E. G., Sterk P. J. The effect of an inhaled leukotriene antagonist, L-648,051, on early and late asthmatic reactions and subsequent increase in airway responsiveness in man. J Allergy Clin Immunol. 1990 Jun;85(6):1067–1075. doi: 10.1016/0091-6749(90)90052-6. [DOI] [PubMed] [Google Scholar]
  8. Britton J. R., Hanley S. P., Tattersfield A. E. The effect of an oral leukotriene D4 antagonist L-649,923 on the response to inhaled antigen in asthma. J Allergy Clin Immunol. 1987 May;79(5):811–816. doi: 10.1016/0091-6749(87)90214-4. [DOI] [PubMed] [Google Scholar]
  9. Broide D. H., Eisman S., Ramsdell J. W., Ferguson P., Schwartz L. B., Wasserman S. I. Airway levels of mast cell-derived mediators in exercise-induced asthma. Am Rev Respir Dis. 1990 Mar;141(3):563–568. doi: 10.1164/ajrccm/141.3.563. [DOI] [PubMed] [Google Scholar]
  10. Christie P. E., Smith C. M., Lee T. H. The potent and selective sulfidopeptide leukotriene antagonist, SK&F 104353, inhibits aspirin-induced asthma. Am Rev Respir Dis. 1991 Oct;144(4):957–958. doi: 10.1164/ajrccm/144.4.957. [DOI] [PubMed] [Google Scholar]
  11. Christie P. E., Tagari P., Ford-Hutchinson A. W., Charlesson S., Chee P., Arm J. P., Lee T. H. Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Respir Dis. 1991 May;143(5 Pt 1):1025–1029. doi: 10.1164/ajrccm/143.5_Pt_1.1025. [DOI] [PubMed] [Google Scholar]
  12. Cloud M. L., Enas G. C., Kemp J., Platts-Mills T., Altman L. C., Townley R., Tinkelman D., King T., Jr, Middleton E., Sheffer A. L. A specific LTD4/LTE4-receptor antagonist improves pulmonary function in patients with mild, chronic asthma. Am Rev Respir Dis. 1989 Nov;140(5):1336–1339. doi: 10.1164/ajrccm/140.5.1336. [DOI] [PubMed] [Google Scholar]
  13. Creticos P. S., Peters S. P., Adkinson N. F., Jr, Naclerio R. M., Hayes E. C., Norman P. S., Lichtenstein L. M. Peptide leukotriene release after antigen challenge in patients sensitive to ragweed. N Engl J Med. 1984 Jun 21;310(25):1626–1630. doi: 10.1056/NEJM198406213102502. [DOI] [PubMed] [Google Scholar]
  14. Cuss F. M., Dixon C. M., Barnes P. J. Effects of inhaled platelet activating factor on pulmonary function and bronchial responsiveness in man. Lancet. 1986 Jul 26;2(8500):189–192. doi: 10.1016/s0140-6736(86)92489-x. [DOI] [PubMed] [Google Scholar]
  15. Dahlén B., Zetterström O., Björck T., Dahlén S. E. The leukotriene-antagonist ICI-204,219 inhibits the early airway reaction to cumulative bronchial challenge with allergen in atopic asthmatics. Eur Respir J. 1994 Feb;7(2):324–331. doi: 10.1183/09031936.94.07020324. [DOI] [PubMed] [Google Scholar]
  16. Dahlén S. E., Hansson G., Hedqvist P., Björck T., Granström E., Dahlén B. Allergen challenge of lung tissue from asthmatics elicits bronchial contraction that correlates with the release of leukotrienes C4, D4, and E4. Proc Natl Acad Sci U S A. 1983 Mar;80(6):1712–1716. doi: 10.1073/pnas.80.6.1712. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Diaz P., Gonzalez M. C., Galleguillos F. R., Ancic P., Cromwell O., Shepherd D., Durham S. R., Gleich G. J., Kay A. B. Leukocytes and mediators in bronchoalveolar lavage during allergen-induced late-phase asthmatic reactions. Am Rev Respir Dis. 1989 Jun;139(6):1383–1389. doi: 10.1164/ajrccm/139.6.1383. [DOI] [PubMed] [Google Scholar]
  18. Dixon R. A., Diehl R. E., Opas E., Rands E., Vickers P. J., Evans J. F., Gillard J. W., Miller D. K. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature. 1990 Jan 18;343(6255):282–284. doi: 10.1038/343282a0. [DOI] [PubMed] [Google Scholar]
  19. Drazen J. M., Austen K. F. Leukotrienes and airway responses. Am Rev Respir Dis. 1987 Oct;136(4):985–998. doi: 10.1164/ajrccm/136.4.985. [DOI] [PubMed] [Google Scholar]
  20. Drazen J. M., O'Brien J., Sparrow D., Weiss S. T., Martins M. A., Israel E., Fanta C. H. Recovery of leukotriene E4 from the urine of patients with airway obstruction. Am Rev Respir Dis. 1992 Jul;146(1):104–108. doi: 10.1164/ajrccm/146.1.104. [DOI] [PubMed] [Google Scholar]
  21. Ferreri N. R., Howland W. C., Stevenson D. D., Spiegelberg H. L. Release of leukotrienes, prostaglandins, and histamine into nasal secretions of aspirin-sensitive asthmatics during reaction to aspirin. Am Rev Respir Dis. 1988 Apr;137(4):847–854. doi: 10.1164/ajrccm/137.4.847. [DOI] [PubMed] [Google Scholar]
  22. Findlay S. R., Barden J. M., Easley C. B., Glass M. Effect of the oral leukotriene antagonist, ICI 204,219, on antigen-induced bronchoconstriction in subjects with asthma. J Allergy Clin Immunol. 1992 May;89(5):1040–1045. doi: 10.1016/0091-6749(92)90227-s. [DOI] [PubMed] [Google Scholar]
  23. Finnerty J. P., Wood-Baker R., Thomson H., Holgate S. T. Role of leukotrienes in exercise-induced asthma. Inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist. Am Rev Respir Dis. 1992 Apr;145(4 Pt 1):746–749. doi: 10.1164/ajrccm/145.4_Pt_1.746. [DOI] [PubMed] [Google Scholar]
  24. Friedman B. S., Bel E. H., Buntinx A., Tanaka W., Han Y. H., Shingo S., Spector R., Sterk P. Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses. Am Rev Respir Dis. 1993 Apr;147(4):839–844. doi: 10.1164/ajrccm/147.4.839. [DOI] [PubMed] [Google Scholar]
  25. Fujimura M., Sasaki F., Nakatsumi Y., Takahashi Y., Hifumi S., Taga K., Mifune J., Tanaka T., Matsuda T. Effects of a thromboxane synthetase inhibitor (OKY-046) and a lipoxygenase inhibitor (AA-861) on bronchial responsiveness to acetylcholine in asthmatic subjects. Thorax. 1986 Dec;41(12):955–959. doi: 10.1136/thx.41.12.955. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Fuller R. W., Black P. N., Dollery C. T. Effect of the oral leukotriene D4 antagonist LY171883 on inhaled and intradermal challenge with antigen and leukotriene D4 in atopic subjects. J Allergy Clin Immunol. 1989 May;83(5):939–944. doi: 10.1016/0091-6749(89)90109-7. [DOI] [PubMed] [Google Scholar]
  27. Fuller R. W., Maltby N., Richmond R., Dollery C. T., Taylor G. W., Ritter W., Philipp E. Oral nafazatrom in man: effect on inhaled antigen challenge. Br J Clin Pharmacol. 1987 Jun;23(6):677–681. doi: 10.1111/j.1365-2125.1987.tb03101.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Gaddy J. N., Margolskee D. J., Bush R. K., Williams V. C., Busse W. W. Bronchodilation with a potent and selective leukotriene D4 (LTD4) receptor antagonist (MK-571) in patients with asthma. Am Rev Respir Dis. 1992 Aug;146(2):358–363. doi: 10.1164/ajrccm/146.2.358. [DOI] [PubMed] [Google Scholar]
  29. Griffin M., Weiss J. W., Leitch A. G., McFadden E. R., Jr, Corey E. J., Austen K. F., Drazen J. M. Effects of leukotriene D on the airways in asthma. N Engl J Med. 1983 Feb 24;308(8):436–439. doi: 10.1056/NEJM198302243080807. [DOI] [PubMed] [Google Scholar]
  30. Hui K. P., Barnes N. C. Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist. Lancet. 1991 May 4;337(8749):1062–1063. doi: 10.1016/0140-6736(91)91709-4. [DOI] [PubMed] [Google Scholar]
  31. Hui K. P., Taylor I. K., Taylor G. W., Rubin P., Kesterson J., Barnes N. C., Barnes P. J. Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients. Thorax. 1991 Mar;46(3):184–189. doi: 10.1136/thx.46.3.184. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Hui K. P., Taylor I. K., Taylor G. W., Rubin P., Kesterson J., Barnes N. C., Barnes P. J. Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients. Thorax. 1991 Mar;46(3):184–189. doi: 10.1136/thx.46.3.184. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Iikura Y., Nagakura T., Walsh G. M., Akimoto K., Kisida M., Kondou T., Odajima Y., Okuma M., Akazawa A., Yukishita T. Role of chemical mediators after antigen and exercise challenge in children with asthma. J Allergy Clin Immunol. 1988 May;81(5 Pt 2):1050–1055. doi: 10.1016/0091-6749(88)90179-0. [DOI] [PubMed] [Google Scholar]
  34. Israel E., Dermarkarian R., Rosenberg M., Sperling R., Taylor G., Rubin P., Drazen J. M. The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. N Engl J Med. 1990 Dec 20;323(25):1740–1744. doi: 10.1056/NEJM199012203232505. [DOI] [PubMed] [Google Scholar]
  35. Israel E., Juniper E. F., Callaghan J. T., Mathur P. N., Morris M. M., Dowell A. R., Enas G. G., Hargreave F. E., Drazen J. M. Effect of a leukotriene antagonist, LY171883, on cold air-induced bronchoconstriction in asthmatics. Am Rev Respir Dis. 1989 Nov;140(5):1348–1353. doi: 10.1164/ajrccm/140.5.1348. [DOI] [PubMed] [Google Scholar]
  36. Israel E., Rubin P., Kemp J. P., Grossman J., Pierson W., Siegel S. C., Tinkelman D., Murray J. J., Busse W., Segal A. T. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med. 1993 Dec 1;119(11):1059–1066. doi: 10.7326/0003-4819-119-11-199312010-00001. [DOI] [PubMed] [Google Scholar]
  37. Kaye M. G., Smith L. J. Effects of inhaled leukotriene D4 and platelet-activating factor on airway reactivity in normal subjects. Am Rev Respir Dis. 1990 Apr;141(4 Pt 1):993–997. doi: 10.1164/ajrccm/141.4_Pt_1.993. [DOI] [PubMed] [Google Scholar]
  38. Kidney J. C., Ridge S. M., Chung K. F., Barnes P. J. Inhibition of platelet-activating factor-induced bronchoconstriction by the leukotriene D4 receptor antagonist ICI 204,219. Am Rev Respir Dis. 1993 Jan;147(1):215–217. doi: 10.1164/ajrccm/147.1.215. [DOI] [PubMed] [Google Scholar]
  39. Kikawa Y., Miyanomae T., Inoue Y., Saito M., Nakai A., Shigematsu Y., Hosoi S., Sudo M. Urinary leukotriene E4 after exercise challenge in children with asthma. J Allergy Clin Immunol. 1992 Jun;89(6):1111–1119. doi: 10.1016/0091-6749(92)90294-c. [DOI] [PubMed] [Google Scholar]
  40. Knapp H. R., Sladek K., Fitzgerald G. A. Increased excretion of leukotriene E4 during aspirin-induced asthma. J Lab Clin Med. 1992 Jan;119(1):48–51. [PubMed] [Google Scholar]
  41. Kumlin M., Dahlén B., Björck T., Zetterström O., Granström E., Dahlén S. E. Urinary excretion of leukotriene E4 and 11-dehydro-thromboxane B2 in response to bronchial provocations with allergen, aspirin, leukotriene D4, and histamine in asthmatics. Am Rev Respir Dis. 1992 Jul;146(1):96–103. doi: 10.1164/ajrccm/146.1.96. [DOI] [PubMed] [Google Scholar]
  42. Lam S., Chan H., LeRiche J. C., Chan-Yeung M., Salari H. Release of leukotrienes in patients with bronchial asthma. J Allergy Clin Immunol. 1988 Apr;81(4):711–717. doi: 10.1016/0091-6749(88)91043-3. [DOI] [PubMed] [Google Scholar]
  43. Lee T. H. Pharmacological modulation of leukotriene and platelet activating factor biosynthesis and activities by alternative dietary fatty acids. Clin Exp Allergy. 1989 Jan;19 (Suppl 1):15–23. [PubMed] [Google Scholar]
  44. Lewis R. A., Austen K. F., Soberman R. J. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med. 1990 Sep 6;323(10):645–655. doi: 10.1056/NEJM199009063231006. [DOI] [PubMed] [Google Scholar]
  45. Lewis R. A., Austen K. F. The biologically active leukotrienes. Biosynthesis, metabolism, receptors, functions, and pharmacology. J Clin Invest. 1984 Apr;73(4):889–897. doi: 10.1172/JCI111312. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. MacGlashan D. W., Jr, Schleimer R. P., Peters S. P., Schulman E. S., Adams G. K., 3rd, Newball H. H., Lichtenstein L. M. Generation of leukotrienes by purified human lung mast cells. J Clin Invest. 1982 Oct;70(4):747–751. doi: 10.1172/JCI110670. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Maltby N. H., Taylor G. W., Ritter J. M., Moore K., Fuller R. W., Dollery C. T. Leukotriene C4 elimination and metabolism in man. J Allergy Clin Immunol. 1990 Jan;85(1 Pt 1):3–9. doi: 10.1016/0091-6749(90)90214-o. [DOI] [PubMed] [Google Scholar]
  48. Mann J. S., Robinson C., Sheridan A. Q., Clement P., Bach M. K., Holgate S. T. Effect of inhaled piriprost (U-60, 257) a novel leukotriene inhibitor, on allergen and exercise induced bronchoconstriction in asthma. Thorax. 1986 Oct;41(10):746–752. doi: 10.1136/thx.41.10.746. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Manning P. J., Rokach J., Malo J. L., Ethier D., Cartier A., Girard Y., Charleson S., O'Byrne P. M. Urinary leukotriene E4 levels during early and late asthmatic responses. J Allergy Clin Immunol. 1990 Aug;86(2):211–220. doi: 10.1016/s0091-6749(05)80068-5. [DOI] [PubMed] [Google Scholar]
  50. Manning P. J., Watson R. M., Margolskee D. J., Williams V. C., Schwartz J. I., O'Byrne P. M. Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist. N Engl J Med. 1990 Dec 20;323(25):1736–1739. doi: 10.1056/NEJM199012203232504. [DOI] [PubMed] [Google Scholar]
  51. Miller D. K., Gillard J. W., Vickers P. J., Sadowski S., Léveillé C., Mancini J. A., Charleson P., Dixon R. A., Ford-Hutchinson A. W., Fortin R. Identification and isolation of a membrane protein necessary for leukotriene production. Nature. 1990 Jan 18;343(6255):278–281. doi: 10.1038/343278a0. [DOI] [PubMed] [Google Scholar]
  52. Naclerio R. M., Baroody F. M., Togias A. G. The role of leukotrienes in allergic rhinitis: a review. Am Rev Respir Dis. 1991 May;143(5 Pt 2):S91–S95. doi: 10.1164/ajrccm/143.5_Pt_2.S91. [DOI] [PubMed] [Google Scholar]
  53. O'Connor B. J., Uden S., Carty T. J., Eskra J. D., Barnes P. J., Chung K. F. Inhibitory effect of UK,74505, a potent and specific oral platelet activating factor (PAF) receptor antagonist, on airway and systemic responses to inhaled PAF in humans. Am J Respir Crit Care Med. 1994 Jul;150(1):35–40. doi: 10.1164/ajrccm.150.1.8025768. [DOI] [PubMed] [Google Scholar]
  54. O'Hickey S. P., Arm J. P., Rees P. J., Spur B. W., Lee T. H. The relative responsiveness to inhaled leukotriene E4, methacholine and histamine in normal and asthmatic subjects. Eur Respir J. 1988 Dec;1(10):913–917. [PubMed] [Google Scholar]
  55. O'Shaughnessy K. M., Taylor I. K., O'Connor B., O'Connell F., Thomson H., Dollery C. T. Potent leukotriene D4 receptor antagonist ICI 204,219 given by the inhaled route inhibits the early but not the late phase of allergen-induced bronchoconstriction. Am Rev Respir Dis. 1993 Jun;147(6 Pt 1):1431–1435. doi: 10.1164/ajrccm/147.6_Pt_1.1431. [DOI] [PubMed] [Google Scholar]
  56. Orning L., Kaijser L., Hammarström S. In vivo metabolism of leukotriene C4 in man: urinary excretion of leukotriene E4. Biochem Biophys Res Commun. 1985 Jul 16;130(1):214–220. doi: 10.1016/0006-291x(85)90404-8. [DOI] [PubMed] [Google Scholar]
  57. Orning L., Kaijser L., Hammarström S. In vivo metabolism of leukotriene C4 in man: urinary excretion of leukotriene E4. Biochem Biophys Res Commun. 1985 Jul 16;130(1):214–220. doi: 10.1016/0006-291x(85)90404-8. [DOI] [PubMed] [Google Scholar]
  58. Phillips G. D., Holgate S. T. Interaction of inhaled LTC4 with histamine and PGD2 on airway caliber in asthma. J Appl Physiol (1985) 1989 Jan;66(1):304–312. doi: 10.1152/jappl.1989.66.1.304. [DOI] [PubMed] [Google Scholar]
  59. Pliss L. B., Ingenito E. P., Ingram R. H., Jr, Pichurko B. Assessment of bronchoalveolar cell and mediator response to isocapnic hyperpnea in asthma. Am Rev Respir Dis. 1990 Jul;142(1):73–78. doi: 10.1164/ajrccm/142.1.73. [DOI] [PubMed] [Google Scholar]
  60. Rasmussen J. B., Eriksson L. O., Margolskee D. J., Tagari P., Williams V. C., Andersson K. E. Leukotriene D4 receptor blockade inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthma. J Allergy Clin Immunol. 1992 Aug;90(2):193–201. doi: 10.1016/0091-6749(92)90071-9. [DOI] [PubMed] [Google Scholar]
  61. Robuschi M., Riva E., Fuccella L. M., Vida E., Barnabe R., Rossi M., Gambaro G., Spagnotto S., Bianco S. Prevention of exercise-induced bronchoconstriction by a new leukotriene antagonist (SK&F 104353). A double-blind study versus disodium cromoglycate and placebo. Am Rev Respir Dis. 1992 Jun;145(6):1285–1288. doi: 10.1164/ajrccm/145.6.1285. [DOI] [PubMed] [Google Scholar]
  62. Rubin A. H., Smith L. J., Patterson R. The bronchoconstrictor properties of platelet-activating factor in humans. Am Rev Respir Dis. 1987 Nov;136(5):1145–1151. doi: 10.1164/ajrccm/136.5.1145. [DOI] [PubMed] [Google Scholar]
  63. Sala A., Voelkel N., Maclouf J., Murphy R. C. Leukotriene E4 elimination and metabolism in normal human subjects. J Biol Chem. 1990 Dec 15;265(35):21771–21778. [PubMed] [Google Scholar]
  64. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science. 1983 May 6;220(4597):568–575. doi: 10.1126/science.6301011. [DOI] [PubMed] [Google Scholar]
  65. Schellenberg R. R. Airway responses to platelet-activating factor. Am Rev Respir Dis. 1987 Oct;136(4 Pt 2):S28–S32. doi: 10.1164/ajrccm/136.4_Pt_2.S28. [DOI] [PubMed] [Google Scholar]
  66. Shaw R. J., Fitzharris P., Cromwell O., Wardlaw A. J., Kay A. B. Allergen-induced release of sulphidopeptide leukotrienes (SRS-A) and LTB4 in allergic rhinitis. Allergy. 1985 Jan;40(1):1–6. doi: 10.1111/j.1398-9995.1985.tb04147.x. [DOI] [PubMed] [Google Scholar]
  67. Sladek K., Dworski R., Fitzgerald G. A., Buitkus K. L., Block F. J., Marney S. R., Jr, Sheller J. R. Allergen-stimulated release of thromboxane A2 and leukotriene E4 in humans. Effect of indomethacin. Am Rev Respir Dis. 1990 Jun;141(6):1441–1445. doi: 10.1164/ajrccm/141.6.1441. [DOI] [PubMed] [Google Scholar]
  68. Smith C. M., Christie P. E., Hawksworth R. J., Thien F., Lee T. H. Urinary leukotriene E4 levels after allergen and exercise challenge in bronchial asthma. Am Rev Respir Dis. 1991 Dec;144(6):1411–1413. doi: 10.1164/ajrccm/144.6.1411. [DOI] [PubMed] [Google Scholar]
  69. Smith C. M., Hawksworth R. J., Thien F. C., Christie P. E., Lee T. H. Urinary leukotriene E4 in bronchial asthma. Eur Respir J. 1992 Jun;5(6):693–699. [PubMed] [Google Scholar]
  70. Smith L. J., Rubin A. H., Patterson R. Mechanism of platelet activating factor-induced bronchoconstriction in humans. Am Rev Respir Dis. 1988 May;137(5):1015–1019. doi: 10.1164/ajrccm/137.5.1015. [DOI] [PubMed] [Google Scholar]
  71. Spector S. L., Smith L. J., Glass M. Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group. Am J Respir Crit Care Med. 1994 Sep;150(3):618–623. doi: 10.1164/ajrccm.150.3.8087328. [DOI] [PubMed] [Google Scholar]
  72. Spencer D. A., Evans J. M., Green S. E., Piper P. J., Costello J. F. Participation of the cysteinyl leukotrienes in the acute bronchoconstrictor response to inhaled platelet activating factor in man. Thorax. 1991 Jun;46(6):441–445. doi: 10.1136/thx.46.6.441. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Spencer D. A., Evans J. M., Green S. E., Piper P. J., Costello J. F. Participation of the cysteinyl leukotrienes in the acute bronchoconstrictor response to inhaled platelet activating factor in man. Thorax. 1991 Jun;46(6):441–445. doi: 10.1136/thx.46.6.441. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Tagari P., Rasmussen J. B., Delorme D., Girard Y., Eriksson L. O., Charleson S., Ford-Hutchinson A. W. Comparison of urinary leukotriene E4 and 16-carboxytetranordihydro leukotriene E4 excretion in allergic asthmatics after inhaled antigen. Eicosanoids. 1990;3(2):75–80. [PubMed] [Google Scholar]
  75. Taylor G. W., Taylor I., Black P., Maltby N. H., Turner N., Fuller R. W., Dollery C. T. Urinary leukotriene E4 after antigen challenge and in acute asthma and allergic rhinitis. Lancet. 1989 Mar 18;1(8638):584–588. doi: 10.1016/s0140-6736(89)91611-5. [DOI] [PubMed] [Google Scholar]
  76. Taylor I. K., O'Shaughnessy K. M., Fuller R. W., Dollery C. T. Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet. 1991 Mar 23;337(8743):690–694. doi: 10.1016/0140-6736(91)90277-v. [DOI] [PubMed] [Google Scholar]
  77. Taylor I. K., Shaw R. J. The mechanism of action of corticosteroids in asthma. Respir Med. 1993 May;87(4):261–277. doi: 10.1016/0954-6111(93)90022-r. [DOI] [PubMed] [Google Scholar]
  78. Taylor I. K., Wellings R., Taylor G. W., Fuller R. W. Urinary leukotriene E4 excretion in exercise-induced asthma. J Appl Physiol (1985) 1992 Aug;73(2):743–748. doi: 10.1152/jappl.1992.73.2.743. [DOI] [PubMed] [Google Scholar]
  79. Undem B. J., Pickett W. C., Lichtenstein L. M., Adams G. K., 3rd The effect of indomethacin on immunologic release of histamine and sulfidopeptide leukotrienes from human bronchus and lung parenchyma. Am Rev Respir Dis. 1987 Nov;136(5):1183–1187. doi: 10.1164/ajrccm/136.5.1183. [DOI] [PubMed] [Google Scholar]
  80. Van Vyve T., Chanez P., Bousquet J., Lacoste J. Y., Michel F. B., Godard P. Safety of bronchoalveolar lavage and bronchial biopsies in patients with asthma of variable severity. Am Rev Respir Dis. 1992 Jul;146(1):116–121. doi: 10.1164/ajrccm/146.1.116. [DOI] [PubMed] [Google Scholar]
  81. Verhagen J., Bel E. H., Kijne G. M., Sterk P. J., Bruynzeel P. L., Veldink G. A., Vliegenthart J. F. The excretion of leukotriene E4 into urine following inhalation of leukotriene D4 by human individuals. Biochem Biophys Res Commun. 1987 Oct 29;148(2):864–868. doi: 10.1016/0006-291x(87)90955-7. [DOI] [PubMed] [Google Scholar]
  82. Walters E. H., Gardiner P. V. Bronchoalveolar lavage as a research tool. Thorax. 1991 Sep;46(9):613–618. doi: 10.1136/thx.46.9.613. [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. Wardlaw A. J., Hay H., Cromwell O., Collins J. V., Kay A. B. Leukotrienes, LTC4 and LTB4, in bronchoalveolar lavage in bronchial asthma and other respiratory diseases. J Allergy Clin Immunol. 1989 Jul;84(1):19–26. doi: 10.1016/0091-6749(89)90173-5. [DOI] [PubMed] [Google Scholar]
  84. Weiss J. W., Drazen J. M., McFadden E. R., Jr, Weller P., Corey E. J., Lewis R. A., Austen K. F. Airway constriction in normal humans produced by inhalation of leukotriene D. Potency, time course, and effect of aspirin therapy. JAMA. 1983 May 27;249(20):2814–2817. [PubMed] [Google Scholar]
  85. Weller P. F., Lee C. W., Foster D. W., Corey E. J., Austen K. F., Lewis R. A. Generation and metabolism of 5-lipoxygenase pathway leukotrienes by human eosinophils: predominant production of leukotriene C4. Proc Natl Acad Sci U S A. 1983 Dec;80(24):7626–7630. doi: 10.1073/pnas.80.24.7626. [DOI] [PMC free article] [PubMed] [Google Scholar]
  86. Wenzel S. E., Larsen G. L., Johnston K., Voelkel N. F., Westcott J. Y. Elevated levels of leukotriene C4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. Am Rev Respir Dis. 1990 Jul;142(1):112–119. doi: 10.1164/ajrccm/142.1.112. [DOI] [PubMed] [Google Scholar]
  87. Westcott J. Y., Smith H. R., Wenzel S. E., Larsen G. L., Thomas R. B., Felsien D., Voelkel N. F. Urinary leukotriene E4 in patients with asthma. Effect of airways reactivity and sodium cromoglycate. Am Rev Respir Dis. 1991 Jun;143(6):1322–1328. doi: 10.1164/ajrccm/143.6.1322. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES